Developer docs
API playgroundTry for free, no card

Search company profiles

Areteia Therapeutics

Full company profile

uuid0000av1

Namestring
Areteia Therapeutics
Legal namestring
Areteia Therapeutics, Inc.
Websiteurl
areteiatx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Areteia Therapeutics was a clinical-stage biopharmaceutical company founded in July 2022 by Knopp Biosciences and Population Health Partners as a dedicated vehicle to develop dexpramipexole, an oral small-molecule drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The company's central thesis was to provide a convenient oral alternative to injectable biologic therapies and chronic corticosteroid use for the eosinophilic asthma subpopulation, with the active ingredient in-licensed/derived from founding asset contributor Knopp Biosciences. Areteia operated as a single-asset, clinical-stage biotech and dosed the first patients in its global Phase III program in March 2023, evaluating dexpramipexole on the primary endpoints of asthma exacerbation reduction and lung-function improvement.

The company was funded exclusively through Series A capital: an initial $350 million tranche led by Bain Capital Life Sciences with participation from Sanofi and a broader investor syndicate in July 2022, followed by a $75 million top-up in February 2024 (also led by Bain Capital Life Sciences with Sanofi re-participating), bringing total Series A funding to $425 million. The February 2024 capital was earmarked for expansion of Phase III development to Japan and other markets, manufacturing, formulation development, and global commercial preparation. Areteia assembled a full clinical-stage management team across medical, development, scientific, commercial, legal, and finance functions, with co-founder Jorge Bartolome as CEO and co-founder Christopher Courts as CFO.

Areteia was a pre-commercial, pre-revenue entity with no approved product and no disclosed pricing model. The company's website now states that it 'is no longer operating,' with correspondence redirected through a Foxboro, MA mailing address and asset inquiries routed to a financial-advisory intermediary (Rock Creek Financial Advisors), indicating a wind-down or asset-disposition restructuring. No acquisition, merger, or licensing outcome for the dexpramipexole program is disclosed in the available data.

Short descriptiontext

Areteia Therapeutics was a clinical-stage biopharmaceutical company (founded 2022) that developed dexpramipexole, an oral small-molecule candidate for eosinophilic asthma, before ceasing operations prior to commercialization.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBernardsville, United States
HQ citystring
Bernardsville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
eosinophilic asthma treatment, oral drug candidates, respiratory therapeutics, clinical-stage biopharmaceutical, eosinophil lowering therapy
Industry1 code
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Respiratory Therapeutics
Social media profiles2 records
Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Areteia Therapeutics is developing dexpramipexole, an oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The lead asset is intended as an oral alternative to injectable biologic therapies and corticosteroids, with the goal of reducing asthma exacerbations and improving lung function. The company was advancing dexpramipexole through Phase III clinical trials as a single-asset clinical-stage biopharmaceutical program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase III clinical trials evaluating efficacy in reducing asthma exacerbations and improving lung function
Product overview1 text field

Areteia Therapeutics was a clinical-stage biopharmaceutical company focused on developing dexpramipexole as an oral treatment for eosinophilic asthma. The company operated as a single-product entity with its lead candidate progressing through Phase III clinical trials. The company is no longer operating.

Product and service1 record
1Dexpramipexole
CategoryRespiratory therapeutics
Description

An oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma, intended as a non-injectable, non-steroidal alternative to biologic therapies and chronic corticosteroids; for patients, prescribers, and payers managing severe eosinophilic asthma.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-12
Description

Co-created Areteia Therapeutics alongside Population Health Partners. Knopp Biosciences contributed dexpramipexole as the lead drug candidate for the new company focused on eosinophilic asthma treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-12
Description

Co-created Areteia Therapeutics alongside Knopp Biosciences to develop and commercialize dexpramipexole as an oral treatment for eosinophilic asthma, providing strategic partnership and operational support.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GSK markets Nucala (mepolizumab), an anti-IL-5 biologic approved for severe eosinophilic asthma. It is the most direct commercial competitor to dexpramipexole's target biology and the standard-of-care incumbent Areteia would have needed to displace.

TypeBroad incumbent
Description

AstraZeneca markets Fasenra (benralizumab), another anti-IL-5 biologic for severe eosinophilic asthma. It is a direct competitor in the eosinophil-targeting asthma space and a benchmark for commercial-stage validation of the underlying mechanism.

TypeDirect peer
Description

Sanofi co-markets Dupixent (dupilumab) with Regeneron for moderate-to-severe asthma and atopic conditions. As an Areteia investor and a developer of the leading asthma biologic, Sanofi is simultaneously a strategic backer and a primary commercial competitor.

TypeBroad incumbent
Description

Regeneron co-develops Dupixent (dupilumab) with Sanofi, the market-leading biologic for type 2 inflammatory asthma. It competes in the same severe asthma patient population Areteia targeted.

TypeDirect peer
Description

Co-founder of Areteia and originator of dexpramipexole. Knopp retained rights to other indications of dexpramipexole (e.g., hypereosinophilic syndrome) and is the upstream R&D parent whose asset powered Areteia's entire pipeline.

TypeBroad incumbent
Description

Teva is a major respiratory therapeutics player (ProAir, AirDuo, generic ICS/LABA combinations) and operates in the asthma commercial landscape where dexpramipexole would have launched.

TypeEmerging player
Description

Vertex has expanded beyond cystic fibrosis into broader respiratory disease and has been active in clinical-stage inflammation/immunology — a comparable late-stage biotech competitor pursuing novel mechanisms in serious respiratory indications.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing inhaled and respiratory-targeted therapeutics. Comparable as a small-cap, late-stage clinical biotech pursuing differentiated mechanisms in pulmonary disease.

TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for severe asthma and other inflammatory diseases. Comparable as a venture-backed, late-clinical-stage respiratory company targeting type 2 inflammation.

TypeEmerging player
Description

Small clinical-stage respiratory company developing inhaled therapeutics for asthma and COPD. Comparable as a niche respiratory biotech focused on differentiated pulmonary drug delivery.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Areteia Therapeutics

Respiratory Therapeuticsareteiatx.com

Areteia Therapeutics was a clinical-stage biopharmaceutical company (founded 2022) that developed dexpramipexole, an oral small-molecule candidate for eosinophilic asthma, before ceasing operations prior to commercialization.

What Areteia Therapeutics does

Areteia Therapeutics was a clinical-stage biopharmaceutical company founded in July 2022 by Knopp Biosciences and Population Health Partners as a dedicated vehicle to develop dexpramipexole, an oral small-molecule drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The company's central thesis was to provide a convenient oral alternative to injectable biologic therapies and chronic corticosteroid use for the eosinophilic asthma subpopulation, with the active ingredient in-licensed/derived from founding asset contributor Knopp Biosciences. Areteia operated as a single-asset, clinical-stage biotech and dosed the first patients in its global Phase III program in March 2023, evaluating dexpramipexole on the primary endpoints of asthma exacerbation reduction and lung-function improvement.

The company was funded exclusively through Series A capital: an initial $350 million tranche led by Bain Capital Life Sciences with participation from Sanofi and a broader investor syndicate in July 2022, followed by a $75 million top-up in February 2024 (also led by Bain Capital Life Sciences with Sanofi re-participating), bringing total Series A funding to $425 million. The February 2024 capital was earmarked for expansion of Phase III development to Japan and other markets, manufacturing, formulation development, and global commercial preparation. Areteia assembled a full clinical-stage management team across medical, development, scientific, commercial, legal, and finance functions, with co-founder Jorge Bartolome as CEO and co-founder Christopher Courts as CFO.

Areteia was a pre-commercial, pre-revenue entity with no approved product and no disclosed pricing model. The company's website now states that it 'is no longer operating,' with correspondence redirected through a Foxboro, MA mailing address and asset inquiries routed to a financial-advisory intermediary (Rock Creek Financial Advisors), indicating a wind-down or asset-disposition restructuring. No acquisition, merger, or licensing outcome for the dexpramipexole program is disclosed in the available data.

Areteia Therapeutics firmographics

Firmographics
Name
Areteia Therapeutics
Legal name
Areteia Therapeutics, Inc.
Website
https://areteiatx.com
Company type
Private
Founded year
2022
Operating status
Closed
Headcount range
11–50 employees
Short description
Areteia Therapeutics was a clinical-stage biopharmaceutical company (founded 2022) that developed dexpramipexole, an oral small-molecule candidate for eosinophilic asthma, before ceasing operations prior to commercialization.
Ownership category
akta.pro rank

Areteia Therapeutics industry classification

Industry
Product category
Respiratory Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Eosinophilic asthma treatment
  • Oral drug candidates
  • Respiratory therapeutics
  • Clinical-stage biopharmaceutical
  • Eosinophil lowering therapy

Where Areteia Therapeutics is headquartered

Location

Headquarters

HQ city
Bernardsville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Areteia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Areteia Therapeutics product offering

Product offering

Core offering

Areteia Therapeutics is developing dexpramipexole, an oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The lead asset is intended as an oral alternative to injectable biologic therapies and corticosteroids, with the goal of reducing asthma exacerbations and improving lung function. The company was advancing dexpramipexole through Phase III clinical trials as a single-asset clinical-stage biopharmaceutical program.

Product overview

Areteia Therapeutics was a clinical-stage biopharmaceutical company focused on developing dexpramipexole as an oral treatment for eosinophilic asthma. The company operated as a single-product entity with its lead candidate progressing through Phase III clinical trials. The company is no longer operating.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dexpramipexole An oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma, intended as a non-injectable, non-steroidal alternative to biologic therapies and chronic corticosteroids; for patients, prescribers, and payers managing severe eosinophilic asthma.

Quantifiable outcome

  • Phase III clinical trials evaluating efficacy in reducing asthma exacerbations and improving lung function

Companies that use Areteia Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Areteia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Areteia Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Knopp BiosciencescoreStrategic or Co-development Partner · 12 July 2022Co-created Areteia Therapeutics alongside Population Health Partners. Knopp Biosciences contributed dexpramipexole as the lead drug candidate for the new company focused on eosinophilic asthma treatment.
  • Population Health PartnerscoreStrategic or Co-development Partner · 12 July 2022Co-created Areteia Therapeutics alongside Knopp Biosciences to develop and commercialize dexpramipexole as an oral treatment for eosinophilic asthma, providing strategic partnership and operational support.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Areteia Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • GlaxoSmithKline (GSK): GSK markets Nucala (mepolizumab), an anti-IL-5 biologic approved for severe eosinophilic asthma. It is the most direct commercial competitor to dexpramipexole's target biology and the standard-of-care incumbent Areteia would have needed to displace.
  • AstraZeneca: AstraZeneca markets Fasenra (benralizumab), another anti-IL-5 biologic for severe eosinophilic asthma. It is a direct competitor in the eosinophil-targeting asthma space and a benchmark for commercial-stage validation of the underlying mechanism.
  • Regeneron Pharmaceuticals: Regeneron co-develops Dupixent (dupilumab) with Sanofi, the market-leading biologic for type 2 inflammatory asthma. It competes in the same severe asthma patient population Areteia targeted.
  • Teva Pharmaceutical Industries: Teva is a major respiratory therapeutics player (ProAir, AirDuo, generic ICS/LABA combinations) and operates in the asthma commercial landscape where dexpramipexole would have launched.

Direct peers

  • Sanofi: Sanofi co-markets Dupixent (dupilumab) with Regeneron for moderate-to-severe asthma and atopic conditions. As an Areteia investor and a developer of the leading asthma biologic, Sanofi is simultaneously a strategic backer and a primary commercial competitor.
  • Knopp Biosciences: Co-founder of Areteia and originator of dexpramipexole. Knopp retained rights to other indications of dexpramipexole (e.g., hypereosinophilic syndrome) and is the upstream R&D parent whose asset powered Areteia's entire pipeline.

Emerging players

  • Vertex Pharmaceuticals: Vertex has expanded beyond cystic fibrosis into broader respiratory disease and has been active in clinical-stage inflammation/immunology — a comparable late-stage biotech competitor pursuing novel mechanisms in serious respiratory indications.
  • Arcturus Therapeutics: Clinical-stage RNA therapeutics company developing inhaled and respiratory-targeted therapeutics. Comparable as a small-cap, late-stage clinical biotech pursuing differentiated mechanisms in pulmonary disease.
  • Upstream Bio: Clinical-stage biotech developing therapeutics for severe asthma and other inflammatory diseases. Comparable as a venture-backed, late-clinical-stage respiratory company targeting type 2 inflammation.
  • Pulmatrix: Small clinical-stage respiratory company developing inhaled therapeutics for asthma and COPD. Comparable as a niche respiratory biotech focused on differentiated pulmonary drug delivery.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Areteia Therapeutics social profiles

Digital presence

Areteia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Areteia Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Areteia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Areteia Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Areteia Therapeutics

What does Areteia Therapeutics do?

Areteia Therapeutics is developing dexpramipexole, an oral drug candidate designed to lower eosinophil levels in patients with eosinophilic asthma. The lead asset is intended as an oral alternative to injectable biologic therapies and corticosteroids, with the goal of reducing asthma exacerbations and improving lung function. The company was advancing dexpramipexole through Phase III clinical trials as a single-asset clinical-stage biopharmaceutical program.

Is Areteia Therapeutics a public or private company?

Areteia Therapeutics is a private company. It is classified as venture growth investor backed and is currently closed.

When was Areteia Therapeutics founded?

Areteia Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Areteia Therapeutics based?

Areteia Therapeutics is headquartered in Bernardsville, United States, in the North America region.

Who are Areteia Therapeutics's main competitors?

Broad incumbents on record are GlaxoSmithKline (GSK), AstraZeneca, Regeneron Pharmaceuticals and Teva Pharmaceutical Industries. Direct peers are Sanofi and Knopp Biosciences. Emerging players are Vertex Pharmaceuticals, Arcturus Therapeutics, Upstream Bio and Pulmatrix.

Does Areteia Therapeutics have an API?

No public API is recorded for Areteia Therapeutics.

What industry is Areteia Therapeutics in?

Areteia Therapeutics's product category is Respiratory Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tracxn2026 Investor Profile, Portfolio, Team & Investment TrendsThe article presents a 2026 investor profile listing four biotech and health-tech companies: Saama, Fractyl, NewAmsterdam Pharma, and Areteia. It details their founding years, funding stages, total capital raised, and key product or therapeutic developments. The content serves as a directory of company profiles rather than reporting on specific recent corporate events.GlobeNewswireAsthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute AnalyticaThe global asthma drugs market was valued at USD 26.52 billion in 2025 and is projected to reach USD 41.18 billion by 2035 at a CAGR of 4.50%, driven by a seismic shift toward biologic therapies. Key players reported strong revenues in 2024, with Sanofi’s Dupixent generating approximately USD 14,500 million, the Amgen-AstraZeneca joint venture’s Tezspire achieving USD 1,219 million, and GSK’s Nucala and Trelegy recording GBP 432 million and GBP 600 million respectively in Q3 2024. The report highlights strategic trends including ultra-long-acting biologics (GSK’s Depemokimab receiving European backing), regulatory headwinds from HFA propellant phase-down, US pricing reforms with USD 35 out-of-pocket caps, and a robust clinical pipeline with 762+ patients in GSK’s Phase 3 Depemokimab trials and multiple oral therapy programs from Sanofi and Areteia Therapeutics targeting launches between 2025–2027.FierceBiotechOncology biotech Mythic and former fundraising heavyweight Areteia reach end of roadMythic Therapeutics is winding down, selling assets, and terminating its phase 1 NSCLC trial for ADC MYTX-011. The company, which raised $103 million in 2021, has not secured further funding. Areteia Therapeutics also closed after a phase 3 asthma win, having raised $425 million.STATReadout Newsletter: Sarepta, Areteia, Dualitas, ACIPAreteia Therapeutics reported that its experimental drug dexpramipexole met the primary endpoint of a Phase 3 study by improving lung function in patients with a specific type of asthma. The privately held company is currently conducting two additional Phase 3 studies for this treatment. Meanwhile, congressional staffers and policy experts are discussing President Trump's proposed plan to peg U.S. drug prices to international rates.YahooDriving innovation in respiratory health: Areteia’s 2025 milestones and future goalsAreteia Therapeutics presented its 2024 achievements and 2025 plans at the J.P. Morgan Healthcare Conference, focusing on dexpramipexole for eosinophilic asthma. The EXHALE-4 trial is fully enrolled with topline results expected in Q3 2025, and SUSPIRE-1 for COPD is also fully enrolled. The company aims to submit regulatory filings and expand its pipeline.SecSEC FORM DAreteia Therapeutics, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with Cowen and Company, LLC acting as the associated broker or dealer. The filing discloses a total offering amount of $445 million, of which $275 million has been sold to 13 investors, leaving $170 million remaining.LinkedInAreteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic AsthmaAreteia Therapeutics secured an additional $75 million in Series A financing to expand the development of oral dexpramipexole for eosinophilic asthma. The funds will support clinical trials in Japan and other global markets, manufacturing expansion, and the development of a once-daily formulation. Viking Global Investors and Marshall Wace joined the investment syndicate.Venture Capital Access OnlineAreteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic AsthmaAreteia Therapeutics announced an additional $75 million in Series A financing, bringing the total funding for its oral dexpramipexole program in eosinophilic asthma to $425 million. The new capital will support the expansion of Phase III clinical trials into Japan and other global markets, as well as manufacturing and formulation development. Investors Viking Global Investors and Marshall Wace joined the existing syndicate led by Bain Capital Life Sciences to provide this expanded funding.VC News DailyAreteia Therapeutics Lands Additional $75MAreteia Therapeutics announced the successful acquisition of an additional $75 million in Series A financing to enhance its Phase III development of dexpramipexole for eosinophilic asthma, increasing its total Series A funding to $425 million. New investors Viking Global Investors and Marshall Wace joined existing supporters including Bain Capital Life Sciences and Sanofi. This funding aims to develop a potential oral drug targeting severe eosinophilic asthma.Pulse 2.0Areteia Therapeutics: $75 Million Raised To Expand Current Phase III Development Of Dexpramipexole In Eosinophilic AsthmaAreteia Therapeutics raised an additional $75 million in Series A financing, bringing the total funding for this round to $425 million. The capital will support the expansion of its Phase III development program for dexpramipexole in eosinophilic asthma, including adding clinical trials in Japan and other global markets. New investors Viking Global Investors and Marshall Wace joined the existing syndicate led by Bain Capital Life Sciences.